Effects of 15d-PGJ2 on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells

Prostaglandins and Other Lipid Mediators

Volumn 79, Issue 3-4, 2006, Pages 230-244

  Funovics, Philip ^a   Brostjan, Christine ^a   Nigisch, Anneliese ^a   Fila, Anna ^b   Grochot, Anna ^c   Mleczko, Katarzyna ^c   Was, Halina ^c   Weigel, Guenter ^a   Dulak, Jozef ^c   Jozkowicz, Alicja ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Angiogenesis; c myc; Endothelium; Prostaglandins; VEGF

Indexed keywords

15 DEOXY DELTA 12,14 PROSTAGLANDIN J2; BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN GEL; MATRIGEL; MESSENGER RNA; MYC PROTEIN; PROSTAGLANDIN DERIVATIVE; PROTEIN C JUN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CAPILLARY; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MORPHOGENESIS; PROSTAGLANDIN D2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTORS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646089683     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2006.02.002     Document Type: Article

References (52)

1. Risau W. Mechanism of angiogenesis. Nature 386 (1997) 671
2. Yu K., Bayona W., Kallens C.B., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270 (1995) 23975
3. Michalik L., and Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotech 10 (1999) 564
4. Lehmann J.M., Moore L.B., Smith-Olivier T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPARγ). J Biol Chem 270 (1995) 12953
5. Zhu Y., Qi C., Jain S., Rao M.S., and Reddy J.K. Deletion of PBP/PPARBP, the gene for nuclear receptor coactivator peroxisome proliferator-activated receptor-binding protein, results in embryonic lethality. J Biol Chem 272 (1997) 25500
6. Barak Y., Nelson M.C., Ong E.S., et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 4 (1999) 585
7. Ryu S., Zhou S., Ladurner A.G., and Tijan R. The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature 397 (1999) 446
8. Yamakawa K., Hosoi M., Koyama H., et al. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 271 (2000) 571
9. Józkowicz A., Dulak J., Piatkowska E., Placha W., and Dembinska-Kiec A. Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol 47 (2000) 1147
10. Xin X., Yang S., Kowalski J., and Gerritsen M.E. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274 (1999) 9116
11. Bourcier M.N., Sukhova G.K., Libby P., and Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19 (1999) 546
12. 2 induces synthesis of interleukin-8 by endothelial cells in a PPARγ-independent manner. Prostaglandins Other Lipid Mediat 66 (2001) 165
13. 2 upregulates expression of matrix metalloproteinase-1 independently of activation of peroxisome proliferator-activated receptor-γ. Acta Biochim Pol 50 (2003) 677
14. Satoh H., Tsukamoto K., Hashimoto Y., et al. Thiazolidinediones suppress endothelin-1 secretion from bovine endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun 254 (1999) 757
15. Bamba H., Ota S., Kato A., Kawamoto C., and Fujiwara K. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 273 (2000) 485
16. 2+-superoxide dismutase and decrease p22phox message expression in primary endothelial cells. Metabolism 50 (2001) 3
17. Gralinski M.R., Rowse P.E., and Breider M.A. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J Cardiovasc Pharmacol 31 (1998) 909
18. 2. J Biol Chem 274 (1999) 17042
19. Józkowicz A., Dulak J., Nigisch A., et al. Ciglitazone, ligand of peroxisome proliferator-activated receptor-γ inhibits vascular endothelial growth factor activity. Eur Surg 34 (2002) 127
20. Murata T., Hata Y., Ishibashi T., et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 119 (2001) 709
21. Murata T., He S., Hangai M., et al. Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization. Invest Ophtalmol Vis Sci 41 (2000) 2309
22. Sarayba M.A., Li L., Tungsiripat T., et al. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand. Exp Eye Res 80 (2005) 435
23. Panigrahy D., Singer S., Shen L.Q., et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 10 (2002) 923
24. Chomczynki P., and Sacchi N. Single step method of RNA isolation by acid guanidinum thiocyanate-phenol-chlorophorm extraction. Anal Biochem 162 (1987) 159
25. Korff T., and Augustin H.G. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 143 (1998) 1341
26. Gornikiewicz A., Zommer A., Jakesz R., Gnant M., and Brostjan C. Retroviral targeting of proliferating endothelial cells. Acta Biochim Pol 52 (2005) 731
27. Vernon R.B., Angello J.C., Iruela-Arispe M.L., Lane T.F., and Sage E.H. Reorganization of basement membrane matrices by cellular traction promotes the formation of cellular networks in vitro. Lab Invest 66 (1992) 536
28. Asano A., Irie Y., and Saito M. Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes. Mol Cell Endocrin 174 (2001) 71
29. Berger J., and Moller D.E. Mechanism of action of PPARs. Annu Rev Med 53 (2002) 409
30. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1 (1998) 465
31. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., and Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6 (2000) 41
32. Zhang M., Volpert O., Shi Y.H., and Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 6 (2000) 196
33. Belanger A.J., Lu H., Date T., et al. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor γ angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor-α. J Mol Cell Cardiol 34 (2002) 765
34. Guerrin M., Moukadiri H., Chollet P., et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 164 (1995) 385
35. Fong G.H., Rossant J., Gertsenstein M., and Breitman M.L. Role of Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelialium. Nature 376 (1995) 66
36. Ferrara N., and Davies-Smyth T. The biology of vascular endothelial growth factor. Endocrin Rev 18 (1997) 4
37. Ilan N., Mahooti S., and Madri J.A. Distinct signal transduction pathways are utilizes during tube formation and survival phases of angiogenesis in vitro. J Cell Sci 111 (1998) 3621
38. Meissner M., Stein M., Urbich C., et al. PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp-1-dependent DNA binding and transactivation. Circ Res 94 (2004) 324
39. Sassa Y., Hata Y., Aiello L.P., Taniguchi Y., Kohno K., and Ishibashi T. Bifunctional properties of peroxisome proliferator-activated receptor-γ1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. 1. Diabetes 53 (2004) 1222
40. Kihara S., Ouchi N., Funahashi T., et al. Troglitazone enhances glucose and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 136 (1998) 163
41. Padilla J., Kaur K., Harris S.G., and Phipps R.P. PPARγ-mediated regulation of normal and malignant B lineage cells. Ann NY Acad Sci 905 (2000) 97
42. Takashima T., Fujiwara Y., Higuchi K., et al. PPARγ ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 19 (2001) 465
43. 2 on cell proliferation and apoptosis in ECV304 endothelial cells. Acta Pharmacol Sin 25 (2004) 47
44. 2 induce apoptosis in Jurkat and Raji cells. Int Immunopharmacol 4 (2004) 1171
45. 2 inhibits expression of eNOS in human endothelial cells. Prostaglandin Other Lipid Mediat 74 (2004) 11
46. 2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways. FEBS Lett 501 (2001) 24
47. 2 inhibits IL-1β-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int 61 (2002) 1957
48. 2. J Biol Chem 278 (2003) 51251
49. Shimada T., Kojima K., Yoshiura K., Hiraishi H., and Terano A. Characteristics of the peroxisome proliferator activated receptor-γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 50 (2002) 658
50. Józkowicz A., Dulak J., Nigisch A., et al. Involvement of nitric oxide in angiogenic activities of vascular endothelial growth factor isoforms. Growth Factors 22 (2004) 19
51. Knies-Bamforth U.E., Fox S.B., Poulsom R., Evan G.I., and Harris A.L. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 64 (2004) 6563
52. Laurora S., Pizzimenti S., Briatore F., et al. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther 305 (2003) 932